Abstract:Environmental risk factors and gene-environment interactions play a critical role in Parkinson's disease (PD). However, the relatively large contribution of environmental risk factors in the overwhelming majority of PD cases has been widely neglected in the field. A "PD prevention agenda" proposed in this journal laid out a set of research priorities focused on preventing PD through modification of environmental risk factors. This agenda includes a call for preclinical studies to employ new high-throughput methods for analyzing transcriptomics and epigenomics to provide a deeper understanding of the effects of exposures linked to PD. Here, we focus on epitranscriptomics as a novel area of research with the potential to add to our understanding of the interplay between genes and environmental exposures in PD. Both epigenetics and epitranscriptomics have been recognized as potential mediators of the complex relationship between genes, environment, and disease. Multiple studies have identified epigenetic alterations, such as DNA methylation, associated with PD and PD-related exposures in human studies and preclinical models. In addition, recent technological advancements have made it possible to study epitranscriptomic RNA modifications, such as RNA N6-methyladenosine (m6A), and a handful of recent studies have begun to explore epitranscriptomics in PD-relevant exposure models. Continued exploration of epitranscriptomic mechanisms in environmentally relevant PD models offers the opportunity to identify biomarkers, pre-degenerative changes that precede symptom onset, and potential mitigation strategies for disease prevention and treatment.

Clinical Perspectives in Epitranscriptomics

Dawn of Epitranscriptomic Medicine

mRNA epitranscriptomics

The rise of epitranscriptomics: recent developments and future directions

Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer

Transcriptome Profiling in Human Diseases: New Advances and Perspectives

Epitranscriptional Regulation: From the Perspectives of Cardiovascular Bioengineering

Mass Spectrometry‐Based Proteomics for Assessing Epitranscriptomic Regulations

Epitranscriptomics in metabolic disease

From the RNA world to the clinic

Leveraging epitranscriptomics for cardiovascular disease theranostics

Clinician's Guide to Epitranscriptomics: An Example of N1-Methyladenosine (m1A) RNA Modification and Cancer

Epitranscriptomic Code and Its Alterations in Human Disease

Epitranscriptomics: A New Layer of microRNA Regulation in Cancer

The Regulation of RNA Modification Systems: The Next Frontier in Epitranscriptomics?

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Detecting the epitranscriptome

Exploring the brain epitranscriptome: perspectives from the NSAS summit

Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson's Disease

RNA editing in the forefront of epitranscriptomics and human health

Bioinformatics approaches for deciphering the epitranscriptome: Recent progress and emerging topics